Top 3 Bladder cancer treatment startups in USA
Jan 10, 2026
|
Like
25
1
Funding: $555.6M
CG Oncology develops oncolytic immunotherapies for patients with advanced bladder cancer. Its flagship drug Cretostimogen is an intravesically administered oncolytic immunotherapy with a dual mechanism of action. It selectively replicates and lyses bladder cancer cells. The rupture of cancer cells can then release tumor-derived antigens, along with GM-CSF, which can stimulate a systemic antitumor immune response involving the body's immune system. CG Oncology has a robust clinical trial program with a developed pipeline to study the safety and efficacy of Cretostimogen. It has received FSA Fast Track and Breakthrough Therapy designations from the FDA.
CG Oncology develops oncolytic immunotherapies for patients with advanced bladder cancer. Its flagship drug Cretostimogen is an intravesically administered oncolytic immunotherapy with a dual mechanism of action. It selectively replicates and lyses bladder cancer cells. The rupture of cancer cells can then release tumor-derived antigens, along with GM-CSF, which can stimulate a systemic antitumor immune response involving the body's immune system. CG Oncology has a robust clinical trial program with a developed pipeline to study the safety and efficacy of Cretostimogen. It has received FSA Fast Track and Breakthrough Therapy designations from the FDA.
2
Funding: $112.3M
Insight Molecular Diagnostics (iMDx) develops and provides diagnostic tests for oncology. The company is developing three genetic tests: blood tests for breast and lung cancer and a urine test for bladder cancer. iMDx has also developed a blood-based transplant monitoring test that quantifies the concentration of donor cell-free DNA (dd-cfDNA) after transplantation. The company partners with biotech research laboratories and supplies them with tests intended exclusively for research purposes in oncology and transplantation research projects.
Insight Molecular Diagnostics (iMDx) develops and provides diagnostic tests for oncology. The company is developing three genetic tests: blood tests for breast and lung cancer and a urine test for bladder cancer. iMDx has also developed a blood-based transplant monitoring test that quantifies the concentration of donor cell-free DNA (dd-cfDNA) after transplantation. The company partners with biotech research laboratories and supplies them with tests intended exclusively for research purposes in oncology and transplantation research projects.
3
Funding: $96M
Lantern Pharma is creating the AI platform RADR for the development of oncology drugs. It's mainly used to predict the potential response of patients to drugs. RADR uses publicly available databases, commercial clinical research and trial data, proprietary company data derived from ex vivo 3D tumor transcriptome models, genomic data and drug sensitivity data from a wide range of carefully selected sources that are constantly analyzed, tracked and updated. Currently, the Lantern Pharma's portfolio includes three leading drug candidates and an ADC program for the treatment of 12 oncological diseases, including non-small cell lung cancer (NSCLC), TNBC, Bladder Cancer, Recurrent Non-Hodgkins Lymphoma, select solid tumors
Lantern Pharma is creating the AI platform RADR for the development of oncology drugs. It's mainly used to predict the potential response of patients to drugs. RADR uses publicly available databases, commercial clinical research and trial data, proprietary company data derived from ex vivo 3D tumor transcriptome models, genomic data and drug sensitivity data from a wide range of carefully selected sources that are constantly analyzed, tracked and updated. Currently, the Lantern Pharma's portfolio includes three leading drug candidates and an ADC program for the treatment of 12 oncological diseases, including non-small cell lung cancer (NSCLC), TNBC, Bladder Cancer, Recurrent Non-Hodgkins Lymphoma, select solid tumors
★
See also:
